Protecting brain cells in Parkinson's disease through gut signaling
Neuroprotection by the GUCY2C gut-brain axis in Parkinson's disease
This study is looking at how a specific gut-brain connection might help protect brain cells in people with Parkinson's disease, with the hope of finding new ways to slow down the disease and improve treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10740951 on NIH RePORTER |
What this research studies
This research investigates how the GUCY2C gut-brain axis may protect dopamine neurons from degeneration in Parkinson's disease. By understanding the role of this receptor in mitochondrial function and its connection to brain signaling, the study aims to develop new therapeutic strategies that could prevent the progression of the disease. The approach involves examining the effects of GUCY2C signaling on neuronal health and its potential to mitigate oxidative stress and cell death. Patients may benefit from insights that could lead to innovative treatments targeting the underlying causes of Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are experiencing motor dysfunction or cognitive decline.
Not a fit: Patients with Parkinson's disease who are in advanced stages of the disease or those with other neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or prevent the progression of Parkinson's disease.
How similar studies have performed: Other research has shown promise in targeting gut-brain signaling pathways for neuroprotection, suggesting potential for success in this novel approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Waldman, Scott a — Thomas Jefferson University
- Study coordinator: Waldman, Scott a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.